Immorna and additional in vivo CAR-T startups moved into first-in-human testing for autoimmune disease, extending a growing push toward therapies that aim to avoid full ex vivo manufacturing. Immorna reported treating a systemic sclerosis patient with an in vivo CAR-T approach, highlighting the continued clinical momentum for RNA-enabled and in vivo targeted immune cell programming. The second startup referenced in the report is also entering the clinic with an in vivo CAR-T strategy aimed at autoimmune indications, signaling that developers are increasingly willing to test systemic delivery formats in early clinical settings.